Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma

類似資料

• Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma
  著者:: Cheah, Chan Yoon, 等
  出版事項: (2015)
• Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma
  著者:: Fowler, Nathan H., 等
  出版事項: (2015)
• Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
  著者:: Becnel, Melody R., 等
  出版事項: (2019)
• Safety, activity, and immune effects of lenalidomide and rituximab in untreated indolent lymphoma
  著者:: Fowler, Nathan H, 等
  出版事項: (2014)
• Lenalidomide in follicular lymphoma
  著者:: Flowers, Christopher R., 等
  出版事項: (2020)